Goldman Sachs Group Inc. Increases Gilead Sciences Price Target to GBX 67 (IBT)
Stock analysts at Goldman Sachs Group Inc. boosted their price objective on shares of Gilead Sciences (LON:IBT) from GBX 59 ($0.94) to GBX 67 ($1.06) in a report issued on Wednesday, AnalystRatingsNetwork reports. Goldman Sachs Group Inc.’s price target would indicate a potential downside of 76.07% from the stock’s previous close.
Gilead Sciences (LON:IBT) traded down 0.36% during mid-day trading on Wednesday, hitting GBX 280.00. The stock had a trading volume of 19,223 shares. Gilead Sciences has a 1-year low of GBX 1.94 and a 1-year high of GBX 3.2441. The stock has a 50-day moving average of GBX 2.76 and a 200-day moving average of GBX 2.55.
A number of other firms have also recently commented on IBT. Analysts at Stifel Nicolaus raised their price target on shares of Gilead Sciences (LON:IBT) from GBX 65 ($1.03) to GBX 75 ($1.19) in a research note to investors on Friday, July 26th. They now have a “buy” rating on the stock. Analysts at Lazard Capital Markets raised their price target on shares of Gilead Sciences (LON:IBT) from GBX 63 ($1.00) to GBX 75 ($1.19) in a research note to investors on Friday, July 26th. They now have a “buy” rating on the stock.
Twelve equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of GBX 68.67 ($1.09).
International Biotechnology Trust plc is an investment company. The investment objective of the Company is to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.